One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Verrica Pharmaceuticals Inc.
VRCA · NCM · Healthcare · Biotechnology
Current price
$3.52
52-week range
$3.08 - $9.82
Market cap
$60.47M
Balance sheet
Healthy
-1.54x Concerning
Net cash $9.39M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
0 Risks
0 rewards · 0 risks
Highlights are unavailable right now.
What this company does
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals makes medicines for skin conditions, like a new treatment called YCANTH for warts. Their main income comes from selling these prescription drugs, and this matters because it shows if they are successfully bringing their treatments to patients and making money from them.
How the company got here
Verrica Pharmaceuticals was founded in 2013 with a vision to develop new treatments for skin conditions that lacked effective solutions. The company focused on dermatology, aiming to create prescription treatments for diseases that require medical intervention. A significant turning point was the U.S. Food and Drug Administration (FDA) approval of YCANTH in July 2023, which marked the first regulatory clearance for cantharidin in treating molluscum contagiosum. Verrica also expanded its focus by licensing a drug for skin cancer, broadening its therapeutic areas. The company went public in 2018, navigating the complex path of clinical research, regulatory reviews, and market dynamics inherent in the biotechnology sector.
What it actually does
Verrica Pharmaceuticals is a biotechnology company that develops and sells prescription medications for skin diseases. They focus on conditions that are often underserved by current treatments. Their work involves creating new drugs and drug-device combinations to address specific dermatological issues, aiming to provide effective solutions for patients and healthcare providers. The company's efforts are concentrated on developing treatments that can be administered by medical professionals.
YCANTH (Molluscum Contagiosum and Common Warts)
Verrica's main product, YCANTH (VP-102), is a prescription medication approved for treating molluscum contagiosum, a common viral skin infection, particularly in children. It's a unique drug-device combination that uses a controlled formulation of cantharidin delivered through a special applicator for precise topical application. YCANTH is the first and only FDA-approved treatment for molluscum contagiosum administered by a healthcare professional. The company is also developing YCANTH for common warts, another type of skin infection.
VP-315 (Dermatologic Oncology)
Verrica is also developing VP-315, a potential first-in-class oncolytic peptide therapy for skin cancer. This treatment is designed to be injected directly into tumors to trigger an immune response against cancer cells. Clinical trials have shown promising results in reducing tumor size and achieving complete clearance in some cases of basal cell carcinoma, a common form of skin cancer. Verrica is exploring VP-315 as a non-surgical treatment option for various skin cancers, including basal cell and squamous cell carcinomas.
What management is betting on now
Verrica's current strategy centers on the commercialization of YCANTH for molluscum contagiosum and advancing the development of VP-315 for skin cancer. Management is focused on optimizing sales and marketing efforts for YCANTH, including expanding its reach beyond dermatology offices to pediatricians. For VP-315, the company is working towards Phase 3 clinical trials and engaging with regulatory bodies like the FDA to outline the development pathway. They are also prioritizing operational efficiencies and cost management to support these initiatives and extend their cash runway.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-8.57M
FY2024 Q4
$-16.06M
FY2025 Q2
$-10.04M
FY2025 Q3
$9.69M
FY2025 Q4
$-4.59M
Revenue
$5.86M
Net income
$-13.15M
Diluted EPS
-0.62
Operating cash flow
$-9.28M
Free cash flow
—
Fetching…
Sources
Revenue
$5.02M
Net income
$-9.68M
Diluted EPS
-0.45
Operating cash flow
$-9.16M
Free cash flow
—
Fetching…
Sources
Revenue
$5.09M
Net income
$-8.07M
Diluted EPS
-1.57
Operating cash flow
$-4.59M
Free cash flow
$-4.59M
Fetching…
Sources
Revenue
$14.34M
Net income
$-274.00K
Diluted EPS
-0.03
Operating cash flow
$9.69M
Free cash flow
$9.69M
Fetching…
Sources
Revenue
$12.70M
Net income
$204.00K
Diluted EPS
0.02
Operating cash flow
$-10.04M
Free cash flow
$-10.04M
Fetching…
Sources
Revenue
$3.44M
Net income
$-9.74M
Diluted EPS
-0.10
Operating cash flow
$-12.68M
Free cash flow
—
Fetching…
Sources
Revenue
$344.00K
Net income
$-16.20M
Diluted EPS
-0.18
Operating cash flow
$-16.06M
Free cash flow
$-16.06M
Fetching…
Sources
Revenue
$-1.78M
Net income
$-22.86M
Diluted EPS
-0.49
Operating cash flow
$-8.56M
Free cash flow
$-8.57M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $3.52
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $9.4M - more cash than debt. Interest coverage -1.5x.
Net debt
$-9.39M
Interest coverage
-1.54x
Verrica Pharmaceuticals Inc. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
VRCA
BASELINE
Verrica Pharmaceuticals Inc.
Total debt $1.81M Interest coverage -1.54x This is the baseline the peer rows are being compared against.
What you should know
The case for and against VRCA
0 Rewards
0 Risks
Rewards
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.84x
P/B
14.02x
P/S
1.99x
EV/EBITDA
-1.97x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
37.7%
Operating margin
-194.5%
Net margin
-102.8%
ROE
—
ROA
-44.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.42x
Current ratio
1.45x
Quick ratio
0.99x
Total debt
$1.81M
Total cash
$11.20M
Growth
How the business has been compounding
Revenue TTM
$30.32M
Revenue 5Y CAGR
31.2%
EPS TTM
-1.75
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-13.35M
Free CF TTM
$-17.63M
FCF margin
-58.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—